INDUSTRIAL SPACE LEASEIndustrial Space Lease • March 10th, 2015 • XBiotech Inc. • Pharmaceutical preparations
Contract Type FiledMarch 10th, 2015 Company IndustryTHIS INDUSTRIAL SPACE LEASE (“Lease”), made as of the 14th day of January, 2008 by and between NNN Met Center 4-9, LP, a Texas limited partnership (“Landlord”) acting by and through Triple Net Properties Realty, Inc. (“Agent” for Landlord) and XBiotech USA, Inc., a Delaware corporation (“Tenant”);
XBIOTECH, INC. [ ] Shares of Common Stock No par value per share UNDERWRITING AGREEMENTUnderwriting Agreement • March 10th, 2015 • XBiotech Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 10th, 2015 Company Industry Jurisdiction
ESCROW AGREEMENTEscrow Agreement • March 10th, 2015 • XBiotech Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 10th, 2015 Company Industry JurisdictionThese instructions may be executed in counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • March 10th, 2015 • XBiotech Inc. • Pharmaceutical preparations • Texas
Contract Type FiledMarch 10th, 2015 Company Industry JurisdictionThis Research Collaboration Agreement (“Agreement”) is made effective this 15th day of December, 2014 (“Effective Date”), by and between XBiotech USA, Inc. (“XBiotech”), a Delaware corporation whose principal place of business is located at 8201 East Riverside Drive, Building 4, Suite 100, Austin, TX 78744, and South Texas Blood & Tissue Center, a Texas 501(c)(3) non-profit corporation (“STBTC”), whose principal place of business is located at 6211 IH 10 West, San Antonio, Texas 78201. Individually each may also be referred to herein as a “Party” and collectively referred to as the “Parties”.
CONFIDENTIAL GS SV LICENCE ROWAgreement • March 10th, 2015 • XBiotech Inc. • Pharmaceutical preparations
Contract Type FiledMarch 10th, 2015 Company IndustryConfidential portions of this document have been omitted and have been filed separately with the Securities and Exchange Commission pursuant to an application for confidential treatment requested under Rule 406 of the Securities Act of 1933, as amended. [**] indicates omitted material that is the subject of the confidential treatment request filed separately with the Commission.